SEOUL-SEMICONDUCTOR
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been awarded the German Innovation Award 2019 in the category “Lighting Solution”. Presented by the German Design Council, the award recognized products and solutions from different industries that offer additional benefits and added value compared to previous solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190529005287/en/
Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the world’s first LEDs to produce light that closely matches the spectrum of natural sunlight, delivering human-centric lighting by reaching lower blue light peak similar to sunlight spectral curve possible to reduce scattered reflection and glare. The light sources with SunLike Series LEDs more accurately show the color of objects as they would appear in natural sunlight. It is optimized to natural light spectra and color rendering of CRI-97 – close to CRI-100 of sunlight, and higher than the CRI-80 of conventional LEDs.
SunLike Series natural spectrum LEDs were co-developed through the combination of Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R technology. TRI-R technology, supported by Toshiba Materials, defines its original concept as “the light closest to the sun for human wellbeing.” TRI-R technology enables the spectrum of natural sunlight to be reproduced by a white LED light source technology. TRI-R is a registered trademark of Toshiba Material Co., Ltd.
SunLike Series natural spectrum LEDs have beneficial effects on human health and well-being according to a recent study conducted by Dr. Octavio L. Perez, adjunct researcher in Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the non-visual melanopic stimulus of LED sources. The study showed that SunLike Series LEDs provide up to 21% more melanopic stimulus than conventional LEDs at 4000K, and the same melanopic stimulus as daylight at 6500K. It has also achieved the highest level of eye safety certification from the International Commission on Illumination as an RG-1 level light source with no photo-biological risks.
“We are proud that our SunLike Series natural spectrum LEDs have been named as a winner of German Innovation Award 2019. This recognition confirms that light sources with SunLike Series LEDs certainly bring differentiated value compared to conventional LEDs to lighting industry,” said Carlo Romiti, Europe sales vice president of Seoul Semiconductor. “We will expand global sales market for customers and consumers to experience our human centric lighting solutions to have beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity.”
To learn more about the SunLike Series natural spectrum LEDs, please visit: http://www.seoulsemicon.com/en/technology/Sunlike/
About German Innovation Award
Established by the German Bundestag and with a foundation endowed by members of German industry, the German Design Council works to promote the competitiveness of companies. Since 1953 the competitions organized by the German Design Council honor achievements in design, branding and innovation on an international level. Design, brand and innovation.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005287/en/
Contact:
Seoul Semiconductor Inc. Jeonghee Kim Tel: +82-70-4391-8311 Email: jeonghee.kim@seoulsemicon.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom